Ravidasvir Hydrochloride/Sofosbuvir

盐酸拉维达韦/索磷布韦

Report date: 2026/01/26 20:01:04
NME

Base Information

Drug NameRavidasvir Hydrochloride/Sofosbuvir
Drug Alias Name盐酸瑞维达韦/索磷布韦ASC-18
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsNonstructural protein 5AHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Ravidasvir HydrochlorideSofosbuvir
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesAscletis Pharmaceutical (Zhejiang) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesAscletis Pharma IncAscletis Pharmaceutical (Zhejiang) Co Ltd
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A